Pharmacyte Biotech Inc (OTCMKTS:PMCB)-Short Sellers Alert

Pharmacyte Biotech Inc (OTCMKTS:PMCB)-Short Sellers Alert -Pharmacyte Biotech Inc(OTCMKTS:PMCB) - Short Selling Analysis & Estimates .

Webcide.com Blog : http://www.webcide.com/#!blog/c1a7h

Pharmacyte Biotech Inc(OTCMKTS:PMCB) - Short Selling Price Target $ 0.06

One way to escape your past is to change your name; PharmaCyte Biotech, recently, changed its name from Nuvilex. Under the Nuvilex name, PharmaCyte Biotech or someone acting without their permission appears to have invested in a massive quantity of stock promotions.

Is this firm investing in ongoing research or just “selling stock” or have they been hi-jacked?

Someone is "Pumping and Dumping" Nuvilex/PharmaCyte Biotech's Stock

The firm has changed their name and ticker to (1) escape the hi-jacking or (2) "muddy" the audit trail, escape their past, and reduce transparency.

Why do individuals change their name? Is there any objective evidence to suggest the use of stock promoters to "pump and dump" Nuvilex…by someone?

Paid promotion by Goldman Small Cap Research coupled with a barrage of bullish press releases and tweets have driven PharmaCyte shares up 100% in the past month.

PharmaCyte's market capitalization is $130 million. The company has sub $1 million in cash on its balance sheet, but burns $1 million in cash per quarter. An equity issuance is imminent.

PharmaCyte earned no revenue in the past 2 years. Despite claiming to be a biotech company, it spent less than $1 million on R&D in the past two years.

With limited R&D spend, only 4 employees, persistent dilution to shareholder, consistent use of paid promotion and $77 million in accumulated losses.

The company put up a new, lengthy press release on April 20 but this did not mitigate the slide. The surge of excitement that pushed the price over $0.21 was almost sure to bring profit taking in its wake, seeing how PMCB was recovering from recent 52-week lows that may have scared a few traders.

The pump campaign that has been going on non-stop since the ticker symbol and name change in January is still going strong too. A new email compensated $11,500 was sent on Monday, with Cream Consulting as the paying party once again. The half-promotional, half-informational pieces drummed up by Goldman Small Cap Research keep coming too. One cropped up minutes ago, this time disclosing monetary compensation of $7,500 received for a research report and a “series of articles”.

While the paid email pumpers are kind enough to disclose the third parties paying them to advertise PMCB stock, the Goldman Small Cap Research pieces disclose their compensation comes from an unnamed “third party”.

With over a hundred email pumps, the majority of which are paid, and with paid “research reports” and coverage pieces on the stock, traders would do well to pause and spend a bit more time doing their own research, check the company's progress with the Cell-in-a-Box technology, the progress being made towards advanced trial stages and decide for themselves what to do next.

As a matter of fact, PMCB is one of the most heavily promoted stocks of 2015 so far. There have been over 100 pump emails targeting the company in the new year.

Paid pumps are not a factor to be ignored, no matter what the company in question is. If someone is willing to pay dozens of thousands of dollars for months on end to advertise a stock, it's worth being a bit more careful when looking at it.

To what extent is the closing price per share dependent on the frequency of stock promotions?

Again, the results are a statistician or researcher's dream come true. Nearly 60% of the price per share is driven by the frequency of stock promotions.

Short Sellers Alert Services by Webcide.com

You can read the ongoing Short Sellers Alerts on Webcide.com Blog , and in case you need more detailed information and additional top level short selling alerts please feel free to contact us at webcides@gmail.com , we will update you about our Premium Services for Hedge Funds and Private Investors .



The alerts, research and reports on this website reflect the opinions of Webcide.com only , and we have based our opinions on articles, posts , researches , facts and evidence collected online, deeply analyzed by our financial sentiment engines .



This is not an offer to sell or a solicitation of an offer to buy any security. We strongly recommend that you do your own due diligence before buying or selling any security, and each investor must make any investment decision based on his/her judgment of the market and based upon all available information.



At any time, you should presume that the principals of Webcide.com and/or our clients and/or investors hold trading positions in the securities profiled on the site and therefore stands to realize significant gains in the event that the price of the stocks covered herein rises or declines in conjunction with our investment opinion.